- $9.43bn
- $8.88bn
- $642.82m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.42 | ||
| Price to Tang. Book | 12.45 | ||
| Price to Free Cashflow | 77.67 | ||
| Price to Sales | 15.29 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.7% | ||
| Return on Equity | -9.4% | ||
| Operating Margin | -14.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 490.49 | 516.41 | 618.73 | 610.78 | 642.82 | 620 | 681.58 | 16.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
10x Genomics, Inc. is a life science technology company. The Company's integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems. Its products are used across diverse fields, from cancer research and immunology to neuroscience and developmental biology. Its commercial product portfolio is made up of its Single Cell and Spatial solutions. Its products include its instruments, which include its Chromium instruments, its Visium CytAssist and its Xenium Analyzer, and its consumables, which include proprietary microfluidic chips, slides, reagents and other consumables for its Single Cell and Spatial solutions. It bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. It also provides post-warranty service contracts for its instruments.
Directors
- John Stuelpnagel NEC (63)
- Benjamin Hindson PRE (46)
- Serge Saxonov CEO (44)
- Justin McAnear CFO (45)
- Jean Philibert CHO (61)
- Eric Whitaker GCN (54)
- Bradford Crutchfield OTH (58)
- Ruth De Backer OTH (44)
- Sridhar Kosaraju IND (43)
- Mathai Mammen IND (53)
- Kimberly Popovits IND (62)
- Bryan Roberts IND (54)
- Shehnaaz Suliman IND (49)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 2nd, 2012
- Public Since
- September 12th, 2019
- No. of Shareholders
- 56
- No. of Employees
- 1,178
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 130,291,168
- Address
- 6230 Stoneridge Mall Road, PLEASANTON, 94588
- Web
- https://www.10xgenomics.com
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Latest News for TXG
Upcoming Events for TXG
Q3 2026 10X Genomics Inc Earnings Release
Q3 2026 10x Genomics, Inc. Earnings Call
Q4 2026 10X Genomics Inc Earnings Release
Similar to TXG
Alamar Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
AngioDynamics
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
As of Today at 01:00 UTC, shares in 10x Genomics are trading at $72.39. This share price information is delayed by 15 minutes.
Shares in 10x Genomics last closed at $72.39 and the price had moved by +508.83% over the past 365 days. In terms of relative price strength the 10x Genomics share price has outperformed the S&P500 Index by +421.17% over the past year.
The overall consensus recommendation for 10x Genomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out more10x Genomics does not currently pay a dividend.
10x Genomics does not currently pay a dividend.
10x Genomics does not currently pay a dividend.
To buy shares in 10x Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $72.39, shares in 10x Genomics had a market capitalisation of $9.43bn.
Here are the trading details for 10x Genomics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TXG
Based on an overall assessment of its quality, value and momentum 10x Genomics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 10x Genomics is $73.67. That is 1.77% above the last closing price of $72.39.
Analysts covering 10x Genomics currently have a consensus Earnings Per Share (EPS) forecast of -$0.73 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 10x Genomics. Over the past six months, its share price has outperformed the S&P500 Index by +154.81%.
As of the last closing price of $72.39, shares in 10x Genomics were trading +92.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 10x Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $72.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
10x Genomics' management team is headed by:
- John Stuelpnagel - NEC
- Benjamin Hindson - PRE
- Serge Saxonov - CEO
- Justin McAnear - CFO
- Jean Philibert - CHO
- Eric Whitaker - GCN
- Bradford Crutchfield - OTH
- Ruth De Backer - OTH
- Sridhar Kosaraju - IND
- Mathai Mammen - IND
- Kimberly Popovits - IND
- Bryan Roberts - IND
- Shehnaaz Suliman - IND